Shots:

• Aldeyra has reported the planned advancement of ADX-1612 (HSP90 inhibitor) to clinical testing for COVID-19- and provided an update on ADX-629 (RASP inhibitor) for COVID-19 and other inflammatory diseases
• ADX-1612 has demonstrated nanomolar potency like or greater than Gilead’s remdesivir in an in vitro model and acts by inhibiting the proteins associated with viral replication and infection- thus enhance the activity of other antiviral drugs to treat COVID-19. Pending FDA feedback- an IND submission for ADX-1612 is expected in Q3’20 and the therapy is also being evaluated in P-II EUDARIO study for ovarian ancer
• ADX-629 has accepted for BARDA CoronaWatch meeting- completed its pre-IND submission with the Pulmonary Division of the FDA with its expected submission of an IND in Jun’2020. ADX-629 has demonstrated reductions across a variety of TH1- TH2- and TH17 inflammatory cytokines- while upregulating the IL-10 and also being evaluated in P-IIa clinical study for psoriasis and atopic asthma- expected to be initiated in H2’20

Click here to­ read full press release/ article | Ref: Aldeyra | Image: Aldeyra